Can Increased Body Mass Index Prevent Adequate Ultrasound Examination for Trisomy 21 Risk Assessment?

Determine Cutoff BMI at which transabdominal sonography (TAS) is not satisfactory for aneuploidy risk assessment.

Study Overview

• Status: Completed
• Conditions: Ultrasound Quality
• Intervention / Treatment: Other: ultrasound

Detailed Description

Obesity is a common public health problem which is increasing worldwide at an alarming rate. According to National nutrition survey statistics of 2007, the prevalence of obesity in the kingdom of Saudi Arabia was 23.6% in women and 14% in men. Also the prevalence of overweight in the Saudi community was determined to be 30.7% for men as compared to 28.4% for the women.

First trimester screening between 11-14 weeks gestation is known to be an effective and reliable screening test for Down syndrome and trisomy 18.First trimester screening allows earlier identification of the pregnancy at risk for fetal aneuploidy and anatomic defects, particularly, cardiac anomalies, therefore, providing an option of earlier diagnosis by chorionic villus sampling and analysis of amniocytes.

The well-known association of obesity during pregnancy with a variety of maternal and fetal complications increases the importance of early aneuploidy screening.

Fetal aneuploidy risk assessment is based on a combination of maternal age, prior affected pregnancy or family history, maternal serum biochemical tests and fetal ultrasound markers.

The impact of obesity on the quality of prenatal ultrasound examination is well established with a greater risk for suboptimal visualization, in particular, the fetal cardiac structures and the craniospinal structures only when body mass index above the 90th percentile.

The quality of prenatal screening for aneuploidy via nuchal translucency thickness measurement is significantly limited among obese pregnant women, thus, increased risk of fetal anomalies.

Gandhiet al, have noted that increased BMI is not associated with suboptimal visualization of nuchal translucency, but it is associated with a longer time to perform the first-trimester ultrasound examination for aneuploidy risk assessment, increased need for transvaginal ultrasound examination for optimum nuchal translucency visualization.

There is evidence suggesting that fetal anatomic evaluation in the low-risk gravida can be better accomplished in the first trimester using the transvaginal route, providing a valuable option for obese patients.

• Study Type: Observational
• Enrollment (Actual): 200

Contacts and Locations

Study Locations

• Saudi Arabia
  • Asir,
    • Khamis Mushait,, Asir,, Saudi Arabia, 101
      • antenatal clinic of Armed Forces Hospital, Southern Region

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 20 years to 35 years (ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: Female

• Sampling Method: Non-Probability Sample

Study Population

Inclusion criteria will consist of women who have a live, intrauterine, singleton pregnancy between 11- 14 weeks gestation.

Description

Inclusion Criteria:

• women who have a live, intrauterine, singleton pregnancy between 11- 14 weeks gestation.

Exclusion Criteria:

• multiple gestation.
• fetal size outside of nuchal translucency screening age (crown-rump length (CRL) outside of 46-71 mm).
• presence of a cystic hygroma.
• fetal demise.

Study Plan

How is the study designed?

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
obese pregnant women; With the use of trans-abdominal ultrasound, the following measurements will be recorded: Fetal nuchal translucency thickness.; Nasal bone.; Fetal facio-maxillary angle.; The flow across the tricuspid valve as normal or regurgitated.; A-wave in the ductus venosus as normal or reversed.	Other: ultrasound; trans abdominal or trans vaginal ultrasound to detect some of the soft markers of trisomy screening
lean pregnant women; With the use of trans-abdominal ultrasound, the following measurements will be recorded: Fetal nuchal translucency thickness.; Nasal bone.; Fetal facio-maxillary angle.; The flow across the tricuspid valve as normal or regurgitated.; A-wave in the ductus venosus as normal or reversed.	Other: ultrasound; trans abdominal or trans vaginal ultrasound to detect some of the soft markers of trisomy screening

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Cutoff body mass index for the use of transvaginal ultrasound for aneuploidy risk assessment.	30 minutes

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
The time of the study. (time needed for satisfactory ultrasound risk assessment in minutes)	time needed for satisfactory ultrasound risk assessment in minutes	30 minutes
The tolerance of the woman for trans-vaginal ultrasound.	preference of the patients towards transabdominal and transvaginal ultrasound	30 minutes
The harmful effect to the patient	Infection, Bleeding, Injury to vagina or cervix and uterine irritability.	12 hours

Collaborators and Investigators

• Sponsor: Benha University
• Collaborators: Armed Forces Hospitals, Southern Region, Saudi Arabia
• Investigators: Principal Investigator: magdy eldumairy, Armed Forces Hospitals, Southern Region, Saudi Arabia

Study record dates

Study Major Dates

• Study Start: June 1, 2015
• Primary Completion (ACTUAL): December 1, 2015
• Study Completion (ACTUAL): January 1, 2016

Study Registration Dates

• First Submitted: May 2, 2015
• First Submitted That Met QC Criteria: May 13, 2015
• First Posted (ESTIMATE): May 14, 2015

Study Record Updates

• Last Update Posted (ESTIMATE): January 20, 2016
• Last Update Submitted That Met QC Criteria: January 16, 2016
• Last Verified: January 1, 2016

More Information

Terms related to this study

• Keywords: ultrasound; obesity; trisomy screening
• Additional Relevant MeSH Terms: Pathologic Processes; Nervous System Diseases; Neurologic Manifestations; Neurobehavioral Manifestations; Congenital Abnormalities; Genetic Diseases, Inborn; Intellectual Disability; Abnormalities, Multiple; Chromosome Disorders; Chromosome Aberrations; Aneuploidy; Chromosome Duplication; Down Syndrome; Trisomy
• Other Study ID Numbers: AFHSRMREC/2015/OB/GYNAE/053